Core Viewpoint - Ginkgo Bioworks is settling multiple derivative actions with a total payment of $4,125,000 to be made by the Individual Defendants' Insurers, which is intended to benefit the company and its shareholders [5][7][10]. Summary by Sections Settlement Details - The settlement amount of $4,125,000 will be paid to Ginkgo within 30 days after the court enters the judgment [5]. - The settlement includes all fees and expenses of Plaintiffs' Counsel and Service Awards, which will be paid if approved by the court [5][8]. - Ginkgo will terminate a specific contract and implement corporate governance reforms for at least three years as part of the settlement [6]. Court Approval - A settlement hearing is scheduled for December 18, 2025, where the court will determine the fairness and adequacy of the settlement [9][10]. - Current Ginkgo stockholders have the right to appear at the hearing and object to the settlement or fee amounts [11][12]. Governance Reforms - The Board of Ginkgo has committed to adopting and maintaining comprehensive corporate governance and internal control reforms as part of the settlement [6][7]. - The Board believes the settlement confers substantial benefits to Ginkgo and its stockholders [7]. Legal Proceedings - The derivative actions are being settled in both the Northern District of California and Delaware Chancery Court [5][10]. - The settlement is part of a broader effort to address claims asserted in the derivative actions [6].

Financial Performance & Targets - Ginkgo achieved its target of $250 million in annualized run-rate cost savings from Q1 2024 to Q2 2025[13, 50] - Ginkgo's Q2 2025 Cell Engineering revenue was $39 million, an 8% increase year-over-year[34] - Biosecurity revenue for Q2 2025 was $10 million, a 48% decrease year-over-year[34] - The company reaffirms its total revenue guidance for FY2025, projecting $167-$187 million, including $117-137 million from Cell Engineering and $40+ million from Biosecurity[37, 52] - Ginkgo aims to reach Adjusted EBITDA breakeven by the end of 2026[11, 46, 53] - Ginkgo had $474 million in cash, cash equivalents, and marketable securities with no bank debt[15, 16] Strategic Initiatives - Ginkgo is expanding from its Solutions business into tools, launching its first direct-to-scientist product: a cell-free protein synthesis system[11, 43, 63] - Ginkgo's Automation and Datapoints are establishing themselves as critical tools in AI-enabled science[43, 143] - Ginkgo has sampled flights originating from 128 countries, representing 65% of nations globally[33]

Company Overview - Ginkgo Bioworks is focused on building a leading platform for cell programming and biosecurity [1] - The company offers customizable R&D packages, including protein engineering and nucleic acid design, to accelerate innovation in therapeutics, diagnostics, and manufacturing [3] - Ginkgo Automation provides modular laboratory automation solutions to enhance scientific productivity [3] - Ginkgo Biosecurity is developing next-generation infrastructure and technologies to address biological threats [3] Upcoming Events - Ginkgo Bioworks will host a presentation and Q&A session on August 7, 2025, to review its business performance for Q2 2025 [1] - The session will begin at 5:30 p.m. ET and will be available via webcast on the company's investor relations website [2] - Questions can be submitted in advance through social media or email [2]